Vancouver-based Kardium has raised $143 million in a financing round led by existing investor Fidelity Management & Research Company. The funding will support the completion of the PULSAR clinical study for the Globe Mapping and Ablation System, used to treat atrial fibrillation.
The funds will also help expand Kardium’s manufacturing capabilities and build a clinical support and commercial team for the Globe System’s launch. The Globe System features a catheter with a 122-electrode array and advanced software for rapid pulmonary vein isolation and high-definition mapping.
Want to know more? Check out the source code on Techcouver.